Ashley C. Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Ashley C. Brown has a total of 278 co-authors. Here are the top co-authors by number of shared publications:
Kimberly Nellenbach
Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Raleigh, USA
18 shared publicationsSeema Nandi
Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, NC 27606, USA
14 shared publicationsSanika Pandit
Joint Department of Biomedical Engineering North Carolina State University and University of North Carolina Raleigh North Carolina USA
9 shared publicationsEmily Mihalko
Joint Department of Biomedical Engineering of University of North Carolina, Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
8 shared publications- Michael A. Daniele
North Carolina Viral Vector Initiative in Research and Learning (NC‐VVIRAL) NC State University Raleigh North Carolina USA
8 shared publications Daniel Chester
Joint Department of Biomedical Engineering of University of North Carolina, Chapel Hill and North Carolina State University, Raleigh, USA
7 shared publications
Latest Publications
- 23 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (15) , 6952-6967
Biofunctionalized Porous POMaC Films Promote Cell Adhesion and Infiltration for Tissue Interfaces
Soft, bioresorbable interfaces that support tissue integration while maintaining ionic/electrical signal transmission remain an important materials challenge for tissue-integrating bioelectronic scaffolds. Here, we report the fabrication and evaluation of a planar and porous poly(octamethylene maleate (anhydride) citrate) (POMaC) (dfilm∼ 250–350 μm) and evaluate how porosity and surface biofunctionalization affect cell interactions and electrical signal transmission through the material. Using sacrificial porogens, we produced porous POMaC films with tunable and interconnected pore architectures (dpore from 10 to 120 μm), including bilayer structures comprising a porous, tissue-facing region and a dense supporting layer. Human dermal fibroblasts (HDFns) and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) demonstrated robust adhesion and viability on both planar and porous POMaC, and porous films supported cellular penetration into the film thickness and multicellular clustering within the porous network. Bioadhesive surface coatings (i.e., gelatin, RGD-containing peptide, and laminin) enhanced cell adhesion and spreading, with laminin affording superior iPSC-CM adhesion and spreading relative to uncoated films. Electrochemical impedance spectroscopy (EIS) and electrical stimulation measurements showed that the integration of POMaC films between interdigitated gold electrodes and physiological electrolyte resulted in modest impedance changes compared to bare electrodes, indicating preserved ionic coupling under these test conditions. Notably, porous POMaC films exhibited improved signal preservation relative to non-porous counterparts, consistent with increased ionic accessibility and effective electrode–electrolyte coupling. Collectively, these results support biofunctionalized porous POMaC as a promising bioresorbable interface material that supports 3D cell penetration while enabling electrical signal transmission, motivating future validation in application-relevant bioelectronic sensing formats.
- 23 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (15) , 6952-6967
Biofunctionalized Porous POMaC Films Promote Cell Adhesion and Infiltration for Tissue Interfaces
Soft, bioresorbable interfaces that support tissue integration while maintaining ionic/electrical signal transmission remain an important materials challenge for tissue-integrating bioelectronic scaffolds. Here, we report the fabrication and evaluation of a planar and porous poly(octamethylene maleate (anhydride) citrate) (POMaC) (dfilm∼ 250–350 μm) and evaluate how porosity and surface biofunctionalization affect cell interactions and electrical signal transmission through the material. Using sacrificial porogens, we produced porous POMaC films with tunable and interconnected pore architectures (dpore from 10 to 120 μm), including bilayer structures comprising a porous, tissue-facing region and a dense supporting layer. Human dermal fibroblasts (HDFns) and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) demonstrated robust adhesion and viability on both planar and porous POMaC, and porous films supported cellular penetration into the film thickness and multicellular clustering within the porous network. Bioadhesive surface coatings (i.e., gelatin, RGD-containing peptide, and laminin) enhanced cell adhesion and spreading, with laminin affording superior iPSC-CM adhesion and spreading relative to uncoated films. Electrochemical impedance spectroscopy (EIS) and electrical stimulation measurements showed that the integration of POMaC films between interdigitated gold electrodes and physiological electrolyte resulted in modest impedance changes compared to bare electrodes, indicating preserved ionic coupling under these test conditions. Notably, porous POMaC films exhibited improved signal preservation relative to non-porous counterparts, consistent with increased ionic accessibility and effective electrode–electrolyte coupling. Collectively, these results support biofunctionalized porous POMaC as a promising bioresorbable interface material that supports 3D cell penetration while enabling electrical signal transmission, motivating future validation in application-relevant bioelectronic sensing formats.
- Open Access
- 3 July 2026
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- p. 1-19
Platelet Products and Artificial Platelets for Regenerative Medicine
Platelet products derived from whole blood include platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet lysate (PL) and platelet-derived extracellular vesicles (pEVs). Such products have been utilized for hemostatic purposes and regenerative medicine. Poor shelf life, high cost of storage, immune risk, and constant need for adequate donors has led to the desire for biomaterials that mimic platelet function. Artificial platelets, such as platelet-membrane coated nanoparticles (NPs), platelet-like particles (PLPs), SynthoPlate, and GRGDS-PEG-coated polyurethane NPs, have been designed to mimic platelet functionality and aid in hemostasis. However, their function can be further leveraged for regenerative medicine and wound healing as they interact with activated platelets and fibrin at the region of interest, highlighting their therapeutic potential. Example regenerative applications of both platelet products and artificial platelets include osteogenesis, angiogenesis, soft tissue and dermal healing, and drug or cell delivery. Some instances in platelet products have reached clinical trials, but most of the biomaterial applications in this realm are still in preclinical testing. Research into their regenerative and wound healing capabilities is novel for the field, but the products show tremendous promise in biomedical applications beyond hemostasis.
- 3 July 2026
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- p. 1-19
Open AccessPlatelet Products and Artificial Platelets for Regenerative Medicine
Platelet products derived from whole blood include platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet lysate (PL) and platelet-derived extracellular vesicles (pEVs). Such products have been utilized for hemostatic purposes and regenerative medicine. Poor shelf life, high cost of storage, immune risk, and constant need for adequate donors has led to the desire for biomaterials that mimic platelet function. Artificial platelets, such as platelet-membrane coated nanoparticles (NPs), platelet-like particles (PLPs), SynthoPlate, and GRGDS-PEG-coated polyurethane NPs, have been designed to mimic platelet functionality and aid in hemostasis. However, their function can be further leveraged for regenerative medicine and wound healing as they interact with activated platelets and fibrin at the region of interest, highlighting their therapeutic potential. Example regenerative applications of both platelet products and artificial platelets include osteogenesis, angiogenesis, soft tissue and dermal healing, and drug or cell delivery. Some instances in platelet products have reached clinical trials, but most of the biomaterial applications in this realm are still in preclinical testing. Research into their regenerative and wound healing capabilities is novel for the field, but the products show tremendous promise in biomedical applications beyond hemostasis.
- 2 July 2026
- Published by Springer Nature
- p. 9-14
Platelet Mimicry for Biomechanical Function
- Open Access
- 15 May 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (8) , 1-9
Macroscale and microscale mechanical and biochemical properties of the equine superficial digital flexor tendon are regionally dependent
Objective: To examine regional mechanical and biochemical differences across the length of the equine superficial digital flexor tendon (SDFT). Methods: Equine SDFTs were collected postmortem from 9 donors and divided into proximal, middle, and distal regions based on the location of the musculotendinous and osteotendinous junctions. Tensile testing was performed on samples to obtain macroscale mechanical properties, and atomic force microscopy was done to obtain microscale mechanical properties. Biochemical assays and histological staining were done to assess glycosaminoglycan (GAG), collagen, and DNA content in each region. Results: Regional differences were present in macroscale mechanical properties and biochemical properties. Differences were primarily seen between the middle and distal region, with the distal region having a 3-fold increased GAG content (Δ14.15 µg GAG/mg sample; 95% CI, −0.32 to 28.62) and a 1.67-fold decreased macroscopic tensile modulus (Δ−68.2 MPa; 95% CI, −107.9 to −28.5). A more disorganized collagen fibril matrix was seen in the distal region through histological staining. Conclusions: Mechanical, biochemical, and histological regional differences exist with the equine SDFT. In particular, the distal region showed a disorganized matrix with higher GAG content and decreased modulus in comparison to the proximal and middle regions. Clinical Relevance: Our data provide information that helps better understand normal SDFT function and presentation of tendinopathy by providing regional structural and biochemical and mechanical information within the SDFT.
- 15 May 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (8) , 1-9
Open AccessMacroscale and microscale mechanical and biochemical properties of the equine superficial digital flexor tendon are regionally dependent
Objective: To examine regional mechanical and biochemical differences across the length of the equine superficial digital flexor tendon (SDFT). Methods: Equine SDFTs were collected postmortem from 9 donors and divided into proximal, middle, and distal regions based on the location of the musculotendinous and osteotendinous junctions. Tensile testing was performed on samples to obtain macroscale mechanical properties, and atomic force microscopy was done to obtain microscale mechanical properties. Biochemical assays and histological staining were done to assess glycosaminoglycan (GAG), collagen, and DNA content in each region. Results: Regional differences were present in macroscale mechanical properties and biochemical properties. Differences were primarily seen between the middle and distal region, with the distal region having a 3-fold increased GAG content (Δ14.15 µg GAG/mg sample; 95% CI, −0.32 to 28.62) and a 1.67-fold decreased macroscopic tensile modulus (Δ−68.2 MPa; 95% CI, −107.9 to −28.5). A more disorganized collagen fibril matrix was seen in the distal region through histological staining. Conclusions: Mechanical, biochemical, and histological regional differences exist with the equine SDFT. In particular, the distal region showed a disorganized matrix with higher GAG content and decreased modulus in comparison to the proximal and middle regions. Clinical Relevance: Our data provide information that helps better understand normal SDFT function and presentation of tendinopathy by providing regional structural and biochemical and mechanical information within the SDFT.
- Open Access
- 28 April 2026
- Published by MDPI AG in International Journal of Medical Devices
- Vol. 1 (1) , 1
Advances in Multifunctional Hernia Repair Mesh to Minimize Post-Surgical Complications
As one of the most frequently performed surgeries worldwide, hernia repair addresses a pathological condition caused by muscle weakness and defects in the muscle wall. Despite its prevalence, hernia surgery remains challenging due to complications such as organ occlusion, seroma, persistent pain, tissue adhesions, and wound infection. Surgical meshes have become the preferred choice for abdominal wall hernia repair, aiming to restore the physical integrity and functionality of the musculofascial layers. Although various types of hernia mesh are available on the market to mitigate post-reconstruction complications, none have proven to be a perfect solution for reducing hernia recurrence. In this review, we explore the etiology of hernias, the materials and structures used in designing hernia meshes, and the emerging multifunctional trends aimed at addressing not just one aspect of the complications but the overall range of complications following hernia repair. We discuss strategies to mitigate side effects and establish the characteristics of ideal hernia repair meshes. Lastly, this review outlines future research directions for developing successful hernia repair solutions, emphasizing the need for innovative approaches to enhance patient outcomes and minimize recurrence rates.
- 28 April 2026
- Published by MDPI AG in International Journal of Medical Devices
- Vol. 1 (1) , 1
Open AccessAdvances in Multifunctional Hernia Repair Mesh to Minimize Post-Surgical Complications
As one of the most frequently performed surgeries worldwide, hernia repair addresses a pathological condition caused by muscle weakness and defects in the muscle wall. Despite its prevalence, hernia surgery remains challenging due to complications such as organ occlusion, seroma, persistent pain, tissue adhesions, and wound infection. Surgical meshes have become the preferred choice for abdominal wall hernia repair, aiming to restore the physical integrity and functionality of the musculofascial layers. Although various types of hernia mesh are available on the market to mitigate post-reconstruction complications, none have proven to be a perfect solution for reducing hernia recurrence. In this review, we explore the etiology of hernias, the materials and structures used in designing hernia meshes, and the emerging multifunctional trends aimed at addressing not just one aspect of the complications but the overall range of complications following hernia repair. We discuss strategies to mitigate side effects and establish the characteristics of ideal hernia repair meshes. Lastly, this review outlines future research directions for developing successful hernia repair solutions, emphasizing the need for innovative approaches to enhance patient outcomes and minimize recurrence rates.
- Open Access
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (17) , 5238-5248
Influence of liquid repellency and slipperiness on blood-material interactions
Slippery hydrophilic (SLIC) coatings significantly reduce platelet and leukocyte adhesion. Under dynamic flow, SLIC surfaces not only inhibit clot growth, but also promote clot degradation.
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (17) , 5238-5248
Open AccessInfluence of liquid repellency and slipperiness on blood-material interactions
Slippery hydrophilic (SLIC) coatings significantly reduce platelet and leukocyte adhesion. Under dynamic flow, SLIC surfaces not only inhibit clot growth, but also promote clot degradation.
- Open Access
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (14) , eady7698
Hemostatic B-knob–triggered microgels (BK-TriGs) to address bleeding in neonates
Hemostatic immaturity in neonates presents critical challenges, especially during surgery, where bleeding and thrombosis risks are elevated. Current treatments rely on transfusing adult blood products, which may cause complications resulting from structural and functional differences between neonatal and adult fibrinogen. To address this, we developed hemostatic B-knob–triggered microgels (BK-TriGs) that target and bridge fibrinogen hole b sites. Functionalized with a fibrin hole b–specific peptide, BK-TriGs enhance clot density and resistance to degradation. In vitro studies using neonatal platelet-poor plasma (PPP) showed that at an optimal concentration, BK-TriGs increased clot density by more than 100% and improved stability by reducing fibrinolysis. Under flow conditions, BK-TriGs promoted robust clot formation compared to plasma-only controls. In an in vivo fib-null (Fga−/−) mouse model transfused with neonatal fibrinogen, BK-TriGs reduced blood loss by 50 to 60% and enhanced fibrin deposition at wound sites. This targeted approach offers a safer, more effective hemostatic solution tailored to neonatal clotting needs.
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (14) , eady7698
Open AccessHemostatic B-knob–triggered microgels (BK-TriGs) to address bleeding in neonates
Hemostatic immaturity in neonates presents critical challenges, especially during surgery, where bleeding and thrombosis risks are elevated. Current treatments rely on transfusing adult blood products, which may cause complications resulting from structural and functional differences between neonatal and adult fibrinogen. To address this, we developed hemostatic B-knob–triggered microgels (BK-TriGs) that target and bridge fibrinogen hole b sites. Functionalized with a fibrin hole b–specific peptide, BK-TriGs enhance clot density and resistance to degradation. In vitro studies using neonatal platelet-poor plasma (PPP) showed that at an optimal concentration, BK-TriGs increased clot density by more than 100% and improved stability by reducing fibrinolysis. Under flow conditions, BK-TriGs promoted robust clot formation compared to plasma-only controls. In an in vivo fib-null (Fga−/−) mouse model transfused with neonatal fibrinogen, BK-TriGs reduced blood loss by 50 to 60% and enhanced fibrin deposition at wound sites. This targeted approach offers a safer, more effective hemostatic solution tailored to neonatal clotting needs.
- Open Access
- 15 February 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (37)
Microfluidic Platform for Multiparametric Profiling of Fibrin Permeability, Fibrinolysis, and Cell Invasion
Fibrin's dual role, as a transient scaffold guiding wound repair and as a pathogenic matrix in thrombosis, demands tools that can profile how its transport properties, degradability, and cellular remodeling evolve under different biochemical, engineering, and ultimately patient‐specific conditions. Here, we introduce a single‐channel, H‐junction microfluidic platform that enables multiplexed, real‐time quantification of fibrin permeability, fibrinolysis kinetics, fibroblast invasion, and clot extension within the same hydrogel. Using time‐lapse confocal microscopy, the assay captured solute permeability coefficients from 1.98 × 10 −5 to 1.67 × 10 −4 cm 2 ∙s −1 , fibrinolysis half‐times down to 12 min, and cell migration, with quantitative analysis performed in a ∼3 µL gel volume. Systematic variation of fibrinogen concentration (1.5–10 mg∙mL −1 ) and FXIII crosslink density reveals a 3.7‐fold span in permeability, a ninefold shift in lysis rate, and up to 64% suppression of fibroblast penetration, as fibrinogen concentration increases. Because the chip uses standard soft‐lithography and conventional microscopy tools, it can be integrated into existing microphysiological systems or deployed as a high‐throughput screening tool for anticoagulants, pro‐healing therapies, and patient‐specific risk assessment. This versatile platform thus bridges mechanistic fibrin research and translational biomaterials design, opening new avenues for precision thrombosis modelling and regenerative medicine.
- 15 February 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (37)
Open AccessMicrofluidic Platform for Multiparametric Profiling of Fibrin Permeability, Fibrinolysis, and Cell Invasion
Fibrin's dual role, as a transient scaffold guiding wound repair and as a pathogenic matrix in thrombosis, demands tools that can profile how its transport properties, degradability, and cellular remodeling evolve under different biochemical, engineering, and ultimately patient‐specific conditions. Here, we introduce a single‐channel, H‐junction microfluidic platform that enables multiplexed, real‐time quantification of fibrin permeability, fibrinolysis kinetics, fibroblast invasion, and clot extension within the same hydrogel. Using time‐lapse confocal microscopy, the assay captured solute permeability coefficients from 1.98 × 10 −5 to 1.67 × 10 −4 cm 2 ∙s −1 , fibrinolysis half‐times down to 12 min, and cell migration, with quantitative analysis performed in a ∼3 µL gel volume. Systematic variation of fibrinogen concentration (1.5–10 mg∙mL −1 ) and FXIII crosslink density reveals a 3.7‐fold span in permeability, a ninefold shift in lysis rate, and up to 64% suppression of fibroblast penetration, as fibrinogen concentration increases. Because the chip uses standard soft‐lithography and conventional microscopy tools, it can be integrated into existing microphysiological systems or deployed as a high‐throughput screening tool for anticoagulants, pro‐healing therapies, and patient‐specific risk assessment. This versatile platform thus bridges mechanistic fibrin research and translational biomaterials design, opening new avenues for precision thrombosis modelling and regenerative medicine.
- 18 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1431-1439
Structure-based design of therapeutics to control hemostasis
Hemorrhage causes millions of deaths and hundreds of billions of dollars in medical costs every year, and a large percentage of trauma bleeding–associated deaths occur in the prehospital setting. Bleeding is typically treated with transfused blood products, but this is difficult in the prehospital setting due to limitations in transportation and storage, especially in rural and remote military settings. Advancements in cold-stored platelets and lyophilized blood products have the potential to address some of these limitations. However, devising novel products that continue to improve shelf life, portability, scalability, cost, and safety for patients experiencing bleeding in prehospital settings could greatly improve treatment options and patient outcomes. This review primarily focuses on rational design of material-based approaches to develop novel hemostatic agents that strive to meet limitations of current blood products, especially for use in the prehospital setting. Key topics of consideration include how material design can lead to identification of effective therapies that stop bleeding as well as strategies to iterate on existing designs to enhance healing after cessation of bleeding. Improving performance and functionality of existing and emerging materials could be achieved through the incorporation of transglutaminases, growth factors, cellular components, or inorganic molecules. Finally, consideration of patient-specific factors that influence bleeding, such as patient sex and age, through evaluation of therapies in specific populations and/or design of materials targeted for specific patient populations, is a key area for development of next-generation hemostatic materials.
- 18 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1431-1439
Structure-based design of therapeutics to control hemostasis
Hemorrhage causes millions of deaths and hundreds of billions of dollars in medical costs every year, and a large percentage of trauma bleeding–associated deaths occur in the prehospital setting. Bleeding is typically treated with transfused blood products, but this is difficult in the prehospital setting due to limitations in transportation and storage, especially in rural and remote military settings. Advancements in cold-stored platelets and lyophilized blood products have the potential to address some of these limitations. However, devising novel products that continue to improve shelf life, portability, scalability, cost, and safety for patients experiencing bleeding in prehospital settings could greatly improve treatment options and patient outcomes. This review primarily focuses on rational design of material-based approaches to develop novel hemostatic agents that strive to meet limitations of current blood products, especially for use in the prehospital setting. Key topics of consideration include how material design can lead to identification of effective therapies that stop bleeding as well as strategies to iterate on existing designs to enhance healing after cessation of bleeding. Improving performance and functionality of existing and emerging materials could be achieved through the incorporation of transglutaminases, growth factors, cellular components, or inorganic molecules. Finally, consideration of patient-specific factors that influence bleeding, such as patient sex and age, through evaluation of therapies in specific populations and/or design of materials targeted for specific patient populations, is a key area for development of next-generation hemostatic materials.
- Open Access
- 24 June 2025
- Published by Elsevier in Matrix Biology Plus
- Vol. 28
Convergence research in matrix biology and biomaterials science
- 24 June 2025
- Published by Elsevier in Matrix Biology Plus
- Vol. 28
Open AccessConvergence research in matrix biology and biomaterials science